Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS
Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Mahmoud M Abdelrazik, Dr
- Phone Number: +201005548881
- Email: dr_mahmoudhosam@yahoo.com
Study Locations
-
-
Dakahlia
-
Mansourah, Dakahlia, Egypt, 35111
- Recruiting
- Obstetrics and Gynecology Department in Mansoura University Hospital
-
Contact:
- Mahmoud M Abdelrazik, Dr
- Phone Number: +201005548881
- Email: dr_mahmoudhosam@yahoo.com
-
Mansourah, Dakahlia, Egypt
- Recruiting
- Private practice settings
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infertile lean women with PCOS as defined by the Rotterdam criteria.
- CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).
Exclusion Criteria:
- Age < 20 or > 35 years.
- Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.
- Presence of any infertility factor other than anovulatory PCOS.
- Previous history of ovarian surgery or surgical removal of one ovary.
- Previous exposure to cytotoxic drugs or pelvic irradiation.
- Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.
- Metabolic or hormonal abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Clomiphene citrate-Prednisolone group
Women will receive clomiphene citrate and prednisolone
|
Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
Other Names:
|
|
Active Comparator: Clomiphene citrate-placebo group
Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
|
Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ovulation rate
Time Frame: 3 months
|
Number of ovulatory cycles divided by the number of stimulation cycles
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical pregnancy rate
Time Frame: 6-8 weeks gestational age
|
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women
|
6-8 weeks gestational age
|
|
Endometrial thickness on day of HCG administration
Time Frame: 3 months
|
Endometrial thickness by TVS on day of HCG administration
|
3 months
|
|
Number of ovarian follicles ≥ 18 mm on day of HCG administration
Time Frame: 3 months
|
Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mahmoud M Abdelrazik, Dr, Mansoura University
- Study Director: Mahmoud Thabet, D, Mansoura University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Syndrome
- Infertility
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Micronutrients
- Hormone Antagonists
- Vitamins
- Anticoagulants
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Hematinics
- Chelating Agents
- Sequestering Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Calcium Chelating Agents
- Prednisolone
- Folic Acid
- Vitamin B Complex
- Citric Acid
- Sodium Citrate
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
Other Study ID Numbers
- MMA1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.